{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:37:30Z","timestamp":1793990250861,"version":"4.8.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"53","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oral complications of cancer treatment are common; however, their clinical and economic importance is often underappreciated. We reviewed the literature on the economic implications of oral complications, updating a previous report in the predecessor to this issue. We searched the Medline and Scopus databases for papers published as of December 31, 2017 that described the economic consequences of preventing and managing oral complications and reviewed the literature reporting the costs of oral mucositis, xerostomia, and osteonecrosis. Cost estimates were inflated to 2017 US dollars. We identified 16 papers describing the cost of managing mucositis, eight describing the cost of osteoradionecrosis, one describing the cost of bisphosphonate-associate osteonecrosis of the jaw, and four describing the cost of xerostomia. The incremental cost of oral mucositis was approximately $5000\u2013$30\u2009000 among patients receiving radiation therapy and $3700 per cycle among patients receiving chemotherapy. The incremental cost of mucositis-related hospitalization among stem cell transplant recipients exceeded $70\u2009000. Conservative management of osteoradionecrosis (antibiotics, debridement) costs $4000\u2013$35\u2009000, although estimates as high as $74 000 have been reported. Hyperbaric oxygen therapy may add $10\u2009000\u2013$50\u2009000 to the cost of therapy. Sialogogues are required for years for the management of xerostomia at a cost of $40\u2013$200 per month. Serious (hospitalization, hyperbaric oxygen therapy) or long-term (sialogogues) outcomes are the major drivers of cost. Future research should address patients\u2019 out-of-pocket costs and the costs of oral complications of new treatments. Multisite studies, particularly those conducted by cooperative groups, should be prioritized.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgz010","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:12:50Z","timestamp":1556824370000},"source":"Crossref","is-referenced-by-count":63,"title":["Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study"],"prefix":"10.1093","volume":"2019","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9058-1827","authenticated-orcid":false,"given":"Linda S","family":"Elting","sequence":"first","affiliation":[{"name":"Department of Health Services Research, University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chia","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, University of Texas M. D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"issue":"9","key":"2020071623550294700_lgz010-B1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40273-013-0081-2","article-title":"The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue","volume":"31","author":"Carlotto","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"29","key":"2020071623550294700_lgz010-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.jncimonographs.a003440","article-title":"Mucositis in head and neck cancer: economic and quality-of-life outcomes","volume":"2001","author":"Peterman","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"2020071623550294700_lgz010-B3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ijrobp.2007.01.053","article-title":"Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies","volume":"68","author":"Elting","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2020071623550294700_lgz010-B4","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cncr.23714","article-title":"Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center","volume":"113","author":"Nonzee","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2020071623550294700_lgz010-B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01769870","article-title":"Cost analysis of long-term feeding by percutaneous endoscopic gastrostomy in cancer patients in an Italian health district","volume":"4","author":"Sartori","year":"1996","journal-title":"Support Care Cancer"},{"issue":"2","key":"2020071623550294700_lgz010-B6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1081\/CNV-100000145","article-title":"Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany","volume":"19","author":"Bennett","year":"2001","journal-title":"Cancer Invest"},{"key":"2020071623550294700_lgz010-B7","author":"Ontario Case Costing Initiative (OCCI), Costing Analysis (CAT) Tool","year":"2011"},{"issue":"7","key":"2020071623550294700_lgz010-B8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/hed.21044","article-title":"Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation","volume":"31","author":"Corry","year":"2009","journal-title":"Head Neck"},{"issue":"3","key":"2020071623550294700_lgz010-B9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.lungcan.2011.04.010","article-title":"Comparison of treatment costs of grade 3\/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain","volume":"74","author":"Banz","year":"2011","journal-title":"Lung Cancer"},{"issue":"8","key":"2020071623550294700_lgz010-B10","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.2001.19.8.2201","article-title":"Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation","volume":"19","author":"Sonis","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020071623550294700_lgz010-B11","first-page":"231","article-title":"Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma","volume":"5","author":"Vera-Llonch","year":"2007","journal-title":"J Support Oncol"},{"issue":"7","key":"2020071623550294700_lgz010-B12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2007.03.004","article-title":"Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results","volume":"13","author":"Elting","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020071623550294700_lgz010-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.2050","article-title":"Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation","volume":"32","author":"Bezinelli","year":"2014","journal-title":"Hematol Oncol"},{"issue":"7","key":"2020071623550294700_lgz010-B14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cncr.11671","article-title":"The burdens of cancer therapy\u2014clinical and economic outcomes of chemotherapy-induced mucositis","volume":"98","author":"Elting","year":"2003","journal-title":"Cancer"},{"key":"2020071623550294700_lgz010-B15","doi-asserted-by":"crossref","DOI":"10.1007\/s10742-006-0015-y","article-title":"Estimating the costs of chemotherapy-associated adverse event clusters","author":"Weiner","year":"2007","journal-title":"Health Serv Outcomes Res Method"},{"issue":"3","key":"2020071623550294700_lgz010-B16","first-page":"3","article-title":"Public health use of inpatient discharge data: a case study of reducing burdens of acute respiratory diseases in Texas with a targeted immunization program","volume":"56","author":"Elting","year":"2004","journal-title":"Texas Public Health J"},{"issue":"4","key":"2020071623550294700_lgz010-B17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/229255039700500401","article-title":"Cost effectiveness analysis of hyperbaric therapy in osteoradionecrosis","volume":"5","author":"Dempsey","year":"1997","journal-title":"Can J Plast Surg"},{"key":"2020071623550294700_lgz010-B18","first-page":"1","year":"2001"},{"key":"2020071623550294700_lgz010-B19","author":"Hyperbaric Oxygen Therapy (HBOT) for the Prevention and Treatment of Osteoradionecrosis Following Radiotherapy of Head and Neck Cancer","year":"2007"},{"issue":"3","key":"2020071623550294700_lgz010-B20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/PRS.0b013e318199f6c6","article-title":"Is simultaneous surgical management of advanced craniofacial osteoradionecrosis cost-effective?","volume":"123","author":"Kelishadi","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"2020071623550294700_lgz010-B21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.clinthera.2011.09.025","article-title":"Economic evaluation of clodronate and zoledronate in patients diagnosed with metastatic bone disease from the perspective of public and third party payors in Brazil","volume":"33","author":"Fonseca","year":"2011","journal-title":"Clin Ther"},{"issue":"9","key":"2020071623550294700_lgz010-B22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1517\/14656566.4.9.1489","article-title":"Efficacy and economic evaluation of pilocarpine in treating radiation-induced xerostomia","volume":"4","author":"Taylor","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2020071623550294700_lgz010-B23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S026646230707033X","article-title":"Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy","volume":"23","author":"Bonastre","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"2020071623550294700_lgz010-B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2009.07.007","article-title":"Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT","volume":"93","author":"Van de Werf","year":"2009","journal-title":"Radiother Oncol"},{"issue":"7","key":"2020071623550294700_lgz010-B25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clon.2012.05.010","article-title":"Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer","volume":"24","author":"Yong","year":"2012","journal-title":"Clin Oncol"},{"issue":"10","key":"2020071623550294700_lgz010-B26","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/cncr.23898","article-title":"Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life","volume":"113","author":"Elting","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"2020071623550294700_lgz010-B27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jpainsymman.2008.12.004","article-title":"Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy","volume":"38","author":"Murphy","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"2020071623550294700_lgz010-B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cncr.21622","article-title":"Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma","volume":"106","author":"Vera-Llonch","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"2020071623550294700_lgz010-B29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-003-0513-1","article-title":"The economic burden of supportive care of cancer patients","volume":"12","author":"Elting","year":"2004","journal-title":"Support Care Cancer"},{"issue":"10","key":"2020071623550294700_lgz010-B30","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/cncr.28592","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"120","author":"Lalla","year":"2014","journal-title":"Cancer"},{"key":"2020071623550294700_lgz010-B31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.oraloncology.2015.10.022","article-title":"Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation","volume":"52","author":"Antunes","year":"2016","journal-title":"Oral Oncol"},{"key":"2020071623550294700_lgz010-B32","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005005.pub2","article-title":"Hyperbaric oxygen therapy for late radiation tissue injury","author":"Bennett","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2020071623550294700_lgz010-B33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1017\/S0022215116009956","article-title":"Cost analysis of osteoradionecrosis","volume":"131","author":"Park","year":"2017","journal-title":"J Laryngol Otol"},{"issue":"3","key":"2020071623550294700_lgz010-B34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bdj.2017.121","article-title":"The financial burden for the surgical management of osteoradionecrosis","volume":"222","author":"Patel","year":"2017","journal-title":"Br Dent J"},{"issue":"1","key":"2020071623550294700_lgz010-B35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.14219\/jada.archive.1985.0074","article-title":"Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin","volume":"111","author":"Marx","year":"1985","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"2020071623550294700_lgz010-B36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/odi.12080","article-title":"Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw","volume":"20","author":"Najm","year":"2014","journal-title":"Oral Dis"},{"key":"2020071623550294700_lgz010-B37","volume-title":"Rare Diseases and Orphan Products: Accelerating Research and Development","author":"Boat","year":"2010"},{"issue":"3","key":"2020071623550294700_lgz010-B38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2005.10.011","article-title":"The impact of introducing intensity modulated radiotherapy into routine clinical practice","volume":"77","author":"Miles","year":"2005","journal-title":"Radiother Oncol"},{"issue":"5","key":"2020071623550294700_lgz010-B39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00520-004-0738-7","article-title":"Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis","volume":"13","author":"Dranitsaris","year":"2005","journal-title":"Support Care Cancer"},{"issue":"8","key":"2020071623550294700_lgz010-B40","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00520-011-1274-x","article-title":"Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer","volume":"20","author":"Ethier","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"2020071623550294700_lgz010-B41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"2020071623550294700_lgz010-B42","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00520-013-1821-8","article-title":"Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis","volume":"21","author":"Elting","year":"2013","journal-title":"Support Care Cancer"},{"key":"2020071623550294700_lgz010-B43","article-title":"Comparative effectiveness and safety of radiotherapy treatments for head and neck cancer","author":"Samson","year":"2010","journal-title":"Comparative effectiveness review no. 20 (prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under contract no. 290-02-0026)"},{"issue":"6","key":"2020071623550294700_lgz010-B44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet Oncol"},{"issue":"17","key":"2020071623550294700_lgz010-B45","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"key":"2020071623550294700_lgz010-B46","author":"Grunberg"},{"issue":"12","key":"2020071623550294700_lgz010-B47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.oraloncology.2009.08.006","article-title":"Mucositis: the impact, biology and therapeutic opportunities of oral mucositis","volume":"45","author":"Sonis","year":"2009","journal-title":"Oral Oncol"},{"issue":"10","key":"2020071623550294700_lgz010-B48","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/annonc\/mdq759","article-title":"Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients","volume":"22","author":"Paessens","year":"2011","journal-title":"Ann Oncol"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncimono\/article-pdf\/2019\/53\/lgz010\/29186759\/lgz010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncimono\/article-pdf\/2019\/53\/lgz010\/29186759\/lgz010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T13:46:46Z","timestamp":1594993606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/doi\/10.1093\/jncimonographs\/lgz010\/5551358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":48,"journal-issue":{"issue":"53","published-online":{"date-parts":[[2019,8,19]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgz010","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,8,1]]},"article-number":"lgz010"}}